Pulmonx Co. (NASDAQ:LUNG) Shares Sold by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC decreased its position in shares of Pulmonx Co. (NASDAQ:LUNG – Get Rating) by 74.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,201 shares of the company’s stock after selling 95,130 shares during the period. Cubist Systematic Strategies LLC owned about 0.09% of Pulmonx worth $536,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of LUNG. Swiss National Bank lifted its stake in Pulmonx by 8.9% during the 1st quarter. Swiss National Bank now owns 47,900 shares of the company’s stock worth $1,188,000 after acquiring an additional 3,900 shares in the last quarter. MetLife Investment Management LLC increased its holdings in Pulmonx by 58.5% during the 1st quarter. MetLife Investment Management LLC now owns 15,791 shares of the company’s stock worth $392,000 after purchasing an additional 5,828 shares during the period. Rhumbline Advisers increased its holdings in Pulmonx by 6.4% during the 1st quarter. Rhumbline Advisers now owns 26,701 shares of the company’s stock worth $662,000 after purchasing an additional 1,617 shares during the period. BlackRock Inc. increased its holdings in Pulmonx by 1.5% during the 1st quarter. BlackRock Inc. now owns 2,760,055 shares of the company’s stock worth $68,477,000 after purchasing an additional 41,724 shares during the period. Finally, Sei Investments Co. increased its holdings in Pulmonx by 36.0% during the 1st quarter. Sei Investments Co. now owns 111,500 shares of the company’s stock worth $2,766,000 after purchasing an additional 29,500 shares during the period. Institutional investors and hedge funds own 92.68% of the company’s stock.

Pulmonx Stock Down 5.8 %

Pulmonx stock opened at $10.74 on Monday. Pulmonx Co. has a twelve month low of $4.07 and a twelve month high of $28.30. The stock has a 50 day moving average of $9.37 and a two-hundred day moving average of $11.10. The company has a current ratio of 9.14, a quick ratio of 8.35 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $404.36 million, a price-to-earnings ratio of -6.75 and a beta of 0.32.

Pulmonx (NASDAQ:LUNG – Get Rating) last posted its quarterly earnings data on Wednesday, February 22nd. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.03. Pulmonx had a negative return on equity of 35.08% and a negative net margin of 109.80%. The company had revenue of $15.40 million during the quarter, compared to analysts’ expectations of $13.98 million. During the same period last year, the firm earned ($0.35) EPS. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. As a group, research analysts expect that Pulmonx Co. will post -1.75 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on LUNG. Canaccord Genuity Group increased their price objective on Pulmonx from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, February 23rd. Bank of America downgraded Pulmonx from a “neutral” rating to an “underperform” rating and set a $8.00 price objective on the stock. in a report on Tuesday, January 3rd. Wells Fargo & Company upgraded Pulmonx from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $10.00 to $15.00 in a research note on Monday, February 27th. Morgan Stanley raised their price target on Pulmonx from $9.50 to $11.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 23rd. Finally, Citigroup raised their price target on Pulmonx from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, February 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Pulmonx has an average rating of “Moderate Buy” and an average target price of $14.38.

Insiders Place Their Bets

In other news, CEO Glendon E. French III sold 2,895 shares of the firm’s stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $11.03, for a total value of $31,931.85. Following the completion of the sale, the chief executive officer now directly owns 1,032,580 shares of the company’s stock, valued at approximately $11,389,357.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders sold 5,365 shares of company stock valued at $59,176. 8.50% of the stock is owned by company insiders.

About Pulmonx

(Get Rating)

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.